ÂÜÀòÂÒÂ×

Fred Meyer is currently the Director at eXIthera. Prior to this, they were with eXIthera Pharmaceuticals LLC, University of Kansas Medical Center, Larta Institute, and Tyrogenex.

At the Larta Institute, Fred worked with NIH-CAP SBIR ventures to commercialize their technologies from January 2009 to December 2012. Fred then became the Vice President of Corporate Development at LipimetiX Development LLC from January 2010 to December 2014. In this role, they were responsible for the creation and development of the company's strategy, as well as identifying and executing business development opportunities.

In January 2013, Fred became a Partner and Co-Founder of Benu BioVentures, where they remained until December 2015. During their time there, they helped lead the launch of two new companies in the healthcare space.

Most recently, Fred has been with Tyrogenex as their VP of Business & Corporate Development from January 2015 to December 2016. In this role, they have been developing X-82, an orally-administered targeted treatment for wet AMD and solid tumors. X-82 inhibits both the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). Preliminary data have shown that orally administered X-82 may provide an alternative delivery option to the eyes of patients with wet AMD. In oncology, X-82’s preliminary studies suggest a toxicity profile that may make X-82 an ideal candidate for combination therapy.

Fred Meyer has a PhD in molecular genetics from The Ohio State University. They also have a BS with honors in genetics and development from the University of Illinois Urbana-Champaign. They are also certified from the CFA Institute as a chartered financial analyst.